Skip to main content
SpringerLink
Log in

PHiD-CV takes top spot

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ismaila AS, Pereira JA, Robson RC, Simpson SD, Rawson NS, Standaert BA.Cost effectiveness analysis of the new 10-valent pneumococcal non-typeable haemophilus influenzae protein-D conjugate vaccine in Canada. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 9 abstr. VA2, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

  2. Pereira JA, Ismaila AS, Robson RC, Simpson SD.Reduction of acute otitis media in children: a cost-consequence analysis of the new 10-valent pneumococcal non-typeable haemophilus influenzae protein-D conjugate vaccine compared with the 7-valent pneumococcal vaccine. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 76 abstr. PSS9, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

  3. Ismaila AS, Pereira JA, Robson RC, Rawson NS, Simpson SD, Standaert BA.A simulation modeling of the effect of dosing schedule on the benefit and cost-effectiveness of pneumococcal vaccination in Canada. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 163 abstr. PIH9, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

  4. Bergman A, Borg S, Sobocki P, Persson U.A cost effectiveness analysis of a general vaccination programme with the new 10-valent pneumococcal non-typeable haemophilus influenzae protein-D conjugate vaccine in Sweden. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 165 abstr. PIH18, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

  5. Demarteau N, Standaert B.Comparing cost-effectiveness results: of a cross-sectional population model with a cohort model: the application to pneumococcal conjugate vaccination. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 9 abstr. VA4, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

PHiD-CV takes top spot. Pharmacoecon. Outcomes News 579, 7–8 (2009). https://doi.org/10.2165/00151234-200905790-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905790-00012

Keywords

Search

Navigation